Global Blood Therapeutics – Consensus Indicates Potential 154.5% Upside

Broker Ratings

Global Blood Therapeutics found using ticker (GBT) now have 20 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 138 and 30 with the average target price sitting at 71.2. Now with the previous closing price of 27.98 this indicates there is a potential upside of 154.5%. There is a 50 day moving average of 30.9 and the 200 day MA is 35.24. The market capitalisation for the company is $1,821m. Visit the company website at:

Global Blood Therapeutics, a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. The company offers Oxbryta tablets, an oral, once-daily therapy for sickle cell disease (SCD). It is evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase 2a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing inclacumab, a novel human monoclonal antibody to treat vaso-occlusive crises; and GBT601, a hemoglobin polymerization inhibitor. It has a license and collaboration agreement with Syros Pharmaceuticals to discover, develop, and commercialize therapies for SCD) and beta thalassemia. The company was founded in 2011 and is headquartered in South San Francisco, California.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits
You might also enjoy reading  Global Blood Therapeutics - Consensus Indicates Potential -5.8% Downside
Find more news, interviews, share price & company profile here for:

    Good news travels fast (but only if you make that happen). Share on:


      AIM All Share Index